Anamorelin Hydrochloride

Anamorelin is an oral pill that mimics ghrelin, the 'I'm hungry' hormone, and was developed to treat cancer cachexia - the wasting syndrome where advanced-cancer patients lose weight, muscle, and appetite, and die faster as a result. The molecule is approved in Japan as Adlumiz (Ono Pharmaceutical, 2021) but was refused approval by the FDA in 2017 because it increased weight without improving function [1][5]. The active node trial, NCT03637816, is a 25-patient Phase 2 investigator-led study at MD Anderson in advanced non-small cell lung cancer (NSCLC) - qualitative, hypothesis-generating, not a registration trial [2]. The interesting question isn't whether anamorelin makes patients weigh more (it does); it's whether anyone - Helsinn, Ono, or a new licensee - will mount a Western key program with endpoints the FDA can accept. So far, nothing's announced.

Anamorelin is in an awkward middle state: approved in Japan, rejected in the US, and not currently in a US key trial. Helsinn Healthcare originated the molecule (formerly RC-1291 / ONO-7643) and ran the ROMANA 1 and ROMANA 2 Phase 3 program in NSCLC cachexia (NCT03743064, NCT03743051, n=318 each), both completed [3][4]. Both hit the body weight primary endpoint but missed handgrip strength, which the FDA's 2017 Complete Response Letter identified as the gap [5]. Ono pushed it through to Japanese approval as Adlumiz. The current active US footprint is small-investigator territory: MDACC's qualitative Phase 2 in NSCLC (NCT03637816) and a fatigue-focused Phase 2 in metastatic solid tumors (NCT03035409, n=129) [2][6]. No FDA breakthrough, fast track, or orphan designations are currently in force for cancer cachexia. A 2025 randomized Japanese trial in metastatic urothelial cancer on systemic chemotherapy reported positive weight/anorexia outcomes [7], and the CLEAR-UP protocol (postoperative upper GI cancer) is recruiting in Japan [8]. The molecule is not on a clear path back to FDA review.

Ghrelin is the hormone your stomach releases when it's empty - it travels to the brain and tells you to eat, and it also tells the pituitary to release growth hormone. Anamorelin is a small molecule that binds the same receptor ghrelin uses (GHSR-1a, the growth hormone secretagogue receptor) and turns it on [9]. In cancer cachexia, ghrelin signaling is blunted, appetite collapses, and the body breaks down muscle faster than it builds it. Agonizing GHSR drives food intake up, stimulates growth hormone and IGF-1, and shifts body composition toward lean mass. The biology is well-validated: ghrelin's role in appetite and GH release is textbook endocrinology, and anamorelin reliably increases body weight and lean body mass across trials [10]. The mechanism does what it says on the tin. The unresolved question is downstream: does adding weight and lean mass in a cachectic cancer patient translate to better function, survival, or quality of life? The ROMANA program answered 'partially' - weight yes, handgrip no - and that asymmetry is the entire commercial story. A 2025 review in Anticancer Research lays out the same tension: efficacy on body composition is consistent; clinical meaningfulness is contested [10].

NCT03637816 is a Phase 2, single-center MDACC trial randomizing 25 advanced NSCLC patients with anorexia/cachexia to oral anamorelin 100 mg daily versus placebo [2]. The primary endpoint is not weight or strength - it's 'thematic saturation' from qualitative interviews about patients' anorexia experience at baseline and on treatment. This is a mixed-methods investigator study, not a registration-track design. Enrollment is closed (active, not recruiting). It will not produce data the FDA cares about for an approval decision; it will produce a paper on patient-reported experience. A second active MDACC study (NCT03035409, n=129, Phase 2) uses anamorelin plus exercise and nutrition counseling versus controls in incurable solid tumors, with FACIT-Fatigue as primary endpoint [6]. Also active is a Tufts mechanism-of-action Phase 1 in non-cancer subjects looking at muscle and bone (NCT04021706, n=32, completed) [11]. The Japanese 2025 urothelial RCT (Odagiri et al., Oncologist) is the most clinically meaningful recent trial - randomized, on-treatment population, weight and anorexia endpoints met [7]. None of these are key Western trials.

Our model puts this drug's odds of eventual approval at 2%. That starts from a 13% historical baseline for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and sponsor. The main factors pulling the number down are a weak sponsor approval record, limited earlier-phase results, and smaller-than-usual enrollment; the main factor pushing it up is an above-average number of secondary endpoints. Everything else is close to typical for this stage and has little effect on the estimate.

Efficacy risk is structural, not statistical: anamorelin works on the scale (weight, lean mass) but not on the dynamometer (handgrip), and the FDA already told Helsinn in 2017 that's not enough [5]. Unless someone runs a trial with a different endpoint construct - a patient-reported functional composite, or a survival co-primary - the same wall is still there. Safety risk is modest. The known on-target signals are mild hyperglycemia (ghrelin/GH axis activation raises glucose), transient liver enzyme elevations, and occasional GI effects; nothing has emerged that looks like a black-box driver [10]. The 2026 HGCSG2201 retrospective in GI cachexia identified predictors of early discontinuation, suggesting real-world tolerability is more nuanced than trial data [13]. Commercial risk is the worst of the three. Cancer cachexia is heterogeneous, oncologists deprioritize it against tumor-directed therapy, megestrol is generic and cheap, and payers historically resist paying premium prices for supportive care that doesn't extend survival. Even Adlumiz revenue in Japan is not broken out cleanly in Ono's English-language filings - a signal that the commercial result is modest [14]. Execution risk: no announced Western key sponsor, no licensee outside Ono/Japan, and Helsinn's broader pipeline focus has shifted.

Noise at the node level. NCT03637816 is a qualitative Phase 2 that will produce a journal paper, not a regulatory decision. The signal to watch isn't this trial - it's whether Helsinn, a new Western licensee, or an academic consortium announces a registration program with FDA-aligned endpoints, or whether Ono publishes Japanese real-world survival data from Adlumiz that's strong enough to force a US conversation. The 2025 von Haehling sarcopenia/cachexia endpoints review in J Cachexia Sarcopenia Muscle is worth tracking - it's the kind of regulatory-science paper that could shift FDA willingness on body composition endpoints [15]. Check back when: (a) any sponsor announces a Western Phase 3 with a composite endpoint, (b) Ono reports Adlumiz long-term outcomes data, or (c) FDA holds a public workshop on cachexia endpoints. Until then, the molecule's commercial trajectory is set: a modest Japan-only product with a stalled US story. The investor takeaway is that 'approved drug, new geography' looks easier than it is when the rejection reason was endpoint philosophy, not data quality.